Taro Pharmaceuticals U.S.A., Inc.

Made with TLC – Thin Layer Care ™ Technology, New bébé Bottoms ™ Diaper Rash Crème Spray Combines Zinc Oxide (10%) with Soothing Chamomile and Calendula in a Convenient, No-Touch Spray Application HAWTHORNE, N.Y., March 28, 2024 /PRNewswire/ -- While traditional diaper rash creams are thick, sticky, and messy, Taro's new bébé Bottoms Diaper Rash Crème Spray allows for easy, one-handed application of a gentle spray formula that is touch-free with no rubbing needed. The light spray, which is formulated with 10% zinc oxide, organic chamomile and calendula, effortlessly covers the affected area, creating a protective barrier that helps soothe baby's diaper rash while allowing skin to breath and heal. It's gentle enough to use at each diaper change to help prevent future irritation. "Taro looks to bring forth novel delivery formats and formulas, which is why we are excited about bébé Bottoms unique TLC - Thin Layer Care ™ spray technology, so parents can easily and effectively protect their baby's delicate skin from diaper rash without the need for a messy traditional cream." says Nivaran Kapur, Head of OTC business at Taro. "This is the second brand for children in the Taro branded OTC portfolio, which also includes FeverAll®, a doctor-recommended acetaminophen suppository product for fever and pain in children as young as 6 months of age." Though gentle, new bébé Bottoms is made with 10% zinc oxide, which is dermatologically tested in its efficacy for both preventing and treating diaper rash. The reduced zinc oxide concentration means it can have a thinner consistency that sprays easily and absorbs quickly. In addition, bébé Bottoms is formulated with organic chamomile and calendula, which combine to help soothe and moisturize the skin to support the skin's natural self-healing ability. The bébé Bottoms formulation has undergone multiple dermatological tests to ensure safety and effectiveness. It is free of harsh chemicals, parabens, dyes, and fragrances, making it suitable for delicate, irritated skin. "It acts like a light lotion to hydrate the skin and helps repair the skin for up to 24 hours with each application. When using it at every diaper change, the crème keeps moisture away from irritated skin so it can heal and prevent further irritation, while the convenient spray technology means you do not need to rub the product in, which can further irritate already painful skin," adds Kapur. New bébé Bottoms Diaper Rash Crème Spray is available to purchase on Amazon and will expand to other major retailers in the coming months. To learn more, visit . About Taro Pharmaceuticals U.S.A., Inc. Taro Pharmaceuticals U.S.A., Inc. was founded in 1988 and is based in Hawthorne, New York. Taro Pharmaceuticals U.S.A., Inc. operates as a subsidiary of Taro Pharmaceutical Industries Ltd. Taro is a research-based international pharmaceutical company that was established on the principal that research and development would be the cornerstone of its growth strategy. Providing quality products through scientific innovations, diligence and precision is the goal of all of Taro's research programs. Taro develops high-quality, proprietary, and off-patent pharmaceuticals for markets in the U.S., Canada, Israel and other countries around the world. The Company produces a wide range of prescription and over-the counter products including bébé Bottoms ™, FeverAll® Acetaminophen Suppositories, FeverAll® Liquid Oral Acetaminophen, tablets, capsules, suspensions, solutions, creams, and ointments. SOURCE Taro Pharmaceuticals U.S.A., Inc.

Lab testing found numerous acne products formulated with benzoyl peroxide, including face washes, creams, and spot treatments, degrade to cancer-causing benzene under normal use and handling. LOS ANGELES, March 8, 2024 /PRNewswire/ -- Wisner Baum filed multiple class actions alleging several companies sold benzoyl peroxide (BPO) acne products without warning consumers that they contain unsafe levels of benzene, a potent human carcinogen. Class action attorneys Stephanie B. Sherman and R. Brent Wisner filed the complaints (Example Case: Howard et al. v. Alchemee, LLC and Taro Pharmaceutical USA, Inc., Case No. 2:24-cv-01834) on behalf of consumers who allege the following companies fraudulently marketed and sold acne face washes, creams, and other products when they knew or should have known that the products degrade to benzene: Alchemee, LLC and Taro Pharmaceutical USA, Inc. (Proactiv BPO products) CVS Pharmacy Inc. and CVS Health Corp. (CVS Health Acne Treatment Cream and CVS Health Acne Control Cleanser) RB Health, LLC (Clearasil Rapid Rescue Spot Treatment Cream and Clearasil Stubborn Acne Control 5 in 1 Spot Treatment Cream) Target Corp. (Up & Up BPO products) Genomma Lab USA, Inc. (Asepxia Acne Spot Treatment Cream) Walgreens Boots Alliance, Inc. (Daily Creamy Benzoyl Peroxide Acne Face Wash and Maximum Strength Acne Foaming Wash) The class actions follow independent testing from Valisure, an independent accredited laboratory that uses validated analytical methods to test drugs and consumer products for safety. Valisure tested 99 BPO-formulated products and found that some yielded benzene at levels 800 times 2 ppm, the maximum amount allowed in any U.S. regulated drug. Some of the benzene levels were many times higher than 2 ppm, reaching as high as 1700 ppm for Proactiv's 2.5% BPO Cream and 1600 ppm for Target's Up & Up 2.5% BPO Cream. Valisure included its testing results in a Citizen's Petition to the FDA and demanded an immediate recall of all BPO products to protect public health. According to the lawsuit allegations, the defendant companies continued to advertise and sell BPO products, ignoring the FDA safety alert on the dangers of benzene in consumer products and a directive to test products for benzene. The degradation of benzoyl peroxide to benzene was first reported in scientific literature in 1936, attorneys say, so the companies knew or should have known their products would degrade and form benzene. "These companies say their face washes and creams are safe, but they have no basis to make this claim because they aren't actually testing their products for basic safety," says attorney Stephanie Sherman. "Our clients never would have purchased these products had they known they were exposing themselves to a dangerous carcinogen." About Wisner Baum Los Angeles-based Wisner Baum has successfully litigated cases against many of the world's largest pharmaceutical companies. Since 1985, the firm has earned a reputation for breaking new legal ground, holding corporations accountable, influencing public policy, and raising public awareness on important safety issues. Across all practice areas, the firm has won over $4 billion in settlements and verdicts. Media Contact: Robin McCall Director of Public Relations Wisner Baum [email protected] SOURCE Wisner Baum

PHILADELPHIA, June 24, 2022 /PRNewswire/ -- NastLaw LLC announces if you purchased certain named generic pharmaceutical drugs directly from certain pharmaceutical manufacturers from May 1, 2009 through December 31, 2019 , your rights may be affected by proposed class action settlements. A federal court authorized this notice. This is not a solicitation from a lawyer. What is the lawsuit about? Two proposed settlements (the "Settlements") have been reached in a class action lawsuit ("the Lawsuit"), which alleges that Sun Pharmaceutical Industries, Inc. and its affiliates Caraco Pharmaceutical Laboratories, Ltd., Mutual Pharmaceutical Company, Inc., and URL Pharma, Inc., and Taro Pharmaceuticals U.S.A., Inc. (collectively "Settling Defendants") violated the federal antitrust laws by conspiring with other generic drug manufacturers to fix, maintain, and stabilize prices, rig bids, and engage in market and customer allocations of certain generic drugs (the "Named Generic Drugs"), causing direct purchasers of the Named Generic Drugs to pay more than they should have. The Settling Defendants deny liability as alleged in the Lawsuit. The Court has not decided who is right. The proposed Settlements do not resolve any of the claims of the Settlement Class against the remaining Defendants. The Lawsuit against the remaining Defendants is ongoing. Who is included? The Court certified a Settlement Class that includes all persons or entities, and their successors and assigns, that directly purchased one or more of the Named Generic Drugs from one or more Defendants in the United States and its territories and possessions, at any time during the period from May 1, 2009 through December 31, 2019. Excluded from the Settlement Class are Defendants and their present and former officers, directors, management, employees, subsidiaries, or affiliates, judicial officers and their personnel, and all governmental entities. The Settlement Agreements listing the Named Generic Drugs and Defendants are available on the settlement website: GenericDrugsDirectPurchaserSettlement.com. The Settlement Agreements also are on public file with the United States District Court for the Eastern District of Pennsylvania, 601 Market Street, Philadelphia, PA 19106 in the case In re: Generic Pharmaceuticals Pricing Antitrust Litigation, Case No. 2:16-MD-02724. What do the Settlements provide? The proposed Settlements provide for the following payments by Settling Defendants: (1) $17,357,000 payment by Sun Pharmaceutical Industries, Inc. and its affiliates Caraco Pharmaceutical Laboratories, Ltd., Mutual Pharmaceutical Company, Inc., and URL Pharma, Inc. and (2) $67,643,000 payment by Taro Pharmaceuticals U.S.A., Inc. These payments (collectively $85,000,000) will comprise the total "Settlement Fund." The Settlement Fund may be reduced by up to $10 million or increased to a maximum of $105 million under certain circumstances as explained in the Settlement Agreements. In addition, the attorneys who have worked on the Lawsuit for the Settlement Class will seek Court approval to pay expenses, attorneys' fees of up to one-third of the Settlement Fund, including interest, after expenses (and service awards) are deducted, and service awards for the class representatives (or named plaintiffs) out of the Settlement Fund. Any motion for expenses and service awards and to set aside one-third of the remaining Settlement Fund (plus accrued interest) for payment of attorneys' fees will be posted on the settlement website GenericDrugsDirectPurchaserSettlement.com once they are filed on August 9, 2022. Settlement Class Counsel will file a motion for an award of fees at a later appropriate time. The calculations of the dollar amount that each Settlement Class Member that submits a Claim Form will be paid from the Settlement Fund is set forth in the Plan of Allocation, which also is available on GenericDrugsDirectPurchaserSettlement.com. What are your options? If you are a Settlement Class Member and you do nothing, you will remain in the Settlement Class and be eligible to participate in the Settlements as described in this notice, if the Settlements are approved. However, you will need to complete, sign, and return the Claim Form (once it is sent to you) in order to obtain a payment. It is anticipated that Defendants' sales data will be used to calculate Settlement Class Members' eligible purchases and pro rata share of the Net Settlement Fund, but if such data is not available from Defendants then you may be required to submit data showing your eligible purchases. We do not know when the Claim Forms will be mailed. You should check GenericDrugsDirectPurchaserSettlement.com for information regarding timing. If you did not receive a Notice in the mail, and you think you are a potential Settlement Class Member, please identify yourself or your company by letter to the following address: In re: Generic Pharmaceuticals Pricing Antitrust Litigation – Direct Purchasers, c/o A.B. Data, Ltd., P.O. Box 173095, Milwaukee, WI 53217, or send an email to [email protected], or call 877-315-0583. You may be required to submit proof of a qualifying purchase to establish that you are a member of the Settlement Class. Claimants may also be required to submit purchase data as part of the claims process. As a Settlement Class Member, unless you opt out of the Settlements, you will be bound by all orders and judgments of the Court. In addition, you may request exclusion from (or opt out of) the Settlements and may object to the Settlements if you do not opt out. Instructions for opting out or objecting can be found in the publicly-available case file and website, as described above. You must mail your request to opt out or your objection by September 23, 2022. The Court will hold a Fairness Hearing on December 13, 2022 at 1:30 p.m. EST to decide whether to approve the Settlements and any requests for fees, expenses, and service awards for the class representatives. The Court will also consider a Plan of Allocation for distributing the Settlement Fund to Settlement Class Members. If there are objections, the Court will consider them at the hearing. You do not need to attend the hearing. If you wish to appear at the hearing, you must file a "Notice of Intention to Appear" with the Court and you may hire your own attorney to appear in Court for you at your own expense. For more information: Go to the website: GenericDrugsDirectPurchaserSettlement.com or call 877-315-0583 for more information on the Settlements, the Lawsuit, and your potential rights and options related to the Settlements. The website includes, for example, a list of the generic drugs that you would have had to purchase and a list of the generic drug manufacturers that you would have had to purchase directly from in order to be eligible for a payment. SOURCE NastLaw LLC